NASDAQ:ANIK

Anika Therapeutics - ANIK Stock Forecast, Price & News

$24.62

-0.01 (-0.04%)

(As of 10/6/2022 12:00 AM ET)

Add

Compare

Today's Range: $24.50
▼
$25.01
50-Day Range: $21.74
▼
$24.68
52-Week Range: $19.95
▼
$45.81

Volume: 46,947 shs
Average Volume: 92,185 shs
Market Capitalization: $359.45 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $41.50

Anika Therapeutics MarketRank™ Forecast

Analyst Rating: Hold
2.00 Rating Score
Upside/Downside: 68.6% Upside
$41.50 Price Target
Short Interest: Bearish
6.42% of Float Sold Short
Dividend Strength: N/A
Sustainability: -1.84
Upright™ Environmental Score
News Sentiment: 0.65
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.45) to ($0.43) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.00 out of 5 stars

Medical Sector

708th out of 1,075 stocks

Surgical & Medical Instruments Industry

72nd out of 104 stocks

3.0

Analyst's Opinion

Consensus Rating
Anika Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 2 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $41.50, Anika Therapeutics has a forecasted upside of 68.6% from its current price of $24.62.
Amount of Analyst Coverage
Anika Therapeutics has received no research coverage in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
6.42% of the float of Anika Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Anika Therapeutics has a short interest ratio ("days to cover") of 11, which indicates bearish sentiment.
Change versus previous month
Short interest in Anika Therapeutics has recently decreased by 4.65%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Anika Therapeutics does not currently pay a dividend.
Dividend Growth
Anika Therapeutics does not have a long track record of dividend growth.

3.9

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Anika Therapeutics has received a 53.44% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Nonwoven medical wipes", "Synthetic bone grafts", and "Medical splints" products. See details.
Environmental Sustainability
The Environmental Impact score for Anika Therapeutics is -1.84.

3.1

News and Social Media Coverage

News Sentiment
Anika Therapeutics has a news sentiment score of 0.65. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.42 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Anika Therapeutics this week, compared to 1 article on an average week.
Search Interest
1 people have searched for ANIK on MarketBeat in the last 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Anika Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 3.03% of the stock of Anika Therapeutics is held by insiders.
Percentage Held by Institutions
92.49% of the stock of Anika Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Anika Therapeutics are expected to grow in the coming year, from ($0.45) to ($0.43) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Anika Therapeutics is -32.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Anika Therapeutics is -32.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Anika Therapeutics has a P/B Ratio of 1.24. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Anika Therapeutics (NASDAQ:ANIK) Stock

Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, soft tissue repair, and bone preserving joint technologies in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management product family consists of Monovisc, Orthovisc, Cingal, and Hyvisc that are indicated to provide pain relief from osteoarthritis conditions; and joint preservation and restoration product family comprise a portfolio of approximately 150 bone preserving joint technology products, a line of sports medicine soft tissue repair solutions, and orthopedic regenerative solutions products. The company's non-orthopedic product family include HA-based products for non-orthopedic applications, including adhesion barrier products, advanced wound care products, ophthalmic products, and ear, nose, and throat products. Anika Therapeutics, Inc. was founded in 1983 and is headquartered in Bedford, Massachusetts.

Receive ANIK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Anika Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ANIK Stock News Headlines

October 5, 2022 | finance.yahoo.com

Global Facial Injectables Market Report (2022 to 2027) - Industry Trends, Share, Size, Growth, Opportunity and Forecasts

October 4, 2022 | americanbankingnews.com

Critical Contrast: Anika Therapeutics (NASDAQ:ANIK) & Inari Medical (NASDAQ:NARI)

September 29, 2022 | marketwatch.com

Injectable Hyaluronic Acid Fillers for Orthopedics and Regenerative Medicine Market Expected to Raise at 10.11% CAGR by 2022-2027 | 117 Report Pages

September 29, 2022 | marketwatch.com

Viscosupplementation Market : Competitive Strategy Analysis and Forecast Values 2022-2027

September 28, 2022 | marketwatch.com

Hyaluronic Acid Based Dermal Fillers Market Expected to Raise at 8.95% CAGR by 2022-2027 | 110 Report Pages

September 27, 2022 | benzinga.com

Joint Pain Injections Global Market Report 2022

September 20, 2022 | marketwatch.com

Facial Aesthetics Market Expected to Raise at 13.28% CAGR by 2022-2027 | 115 Report Pages

September 16, 2022 | marketwatch.com

Adhesion Barrier Market reached USD 695 million in 2020 and will grow at 7.9% CAGR during 2021-2028 | Size, Industry Report & Forecast

September 14, 2022 | morningstar.com

Anika Announces First Surgeries Performed Using the X-Twist™ Fixation System and Commences Limited Market Release | Morningstar

September 13, 2022 | uk.finance.yahoo.com

The Global Adhesion Barriers Market is expected to grow by $ 297.84 mn during 2022-2026, accelerating at a CAGR of 6.43% during the forecast period

September 9, 2022 | nz.finance.yahoo.com

Orthopedic Regenerative Surgical Products Global Market Report 2022

August 23, 2022 | marketwatch.com

Burn Care Market Is Expected to Progress at a CAGR of 5.5% between 2022 to 2028 | 100 Report Pages

August 6, 2022 | seekingalpha.com

Anika Therapeutics, Inc. 2022 Q2 - Results - Earnings Call Presentation

August 5, 2022 | benzinga.com

Anika Therapeutics: Q2 Earnings Insights

August 3, 2022 | finance.yahoo.com

Anika Therapeutics (ANIK) Reports Q2 Loss, Tops Revenue Estimates

July 21, 2022 | marketwatch.com

Wound Care Market 2022 Outlook By Industry Size, Share, Revenue, Regions, and Forecast to 2030

July 21, 2022 | finance.yahoo.com

Bullish insiders at Anika Therapeutics, Inc. (NASDAQ:ANIK) loaded up on US$573k of stock earlier this year

July 15, 2022 | marketwatch.com

Hyaluronic Acid Market Application, Product Segment, Analysis and Forecast 2022-2030 Report

July 14, 2022 | marketwatch.com

Autologous Matrix-induced Chondrogenesis Market Share, Industry Size, Opportunities, Analysis and Forecast to 2028

July 11, 2022 | finance.yahoo.com

At 10.8% CAGR, Medical Aesthetics Market to hit USD 19.01 Billion in 2027, Says Brandessence Market Research

July 6, 2022 | marketwatch.com

Facial Aesthetics Market Size 2022 Research Findings, Market Growth Factors Analysis and Forecasts 2026

July 6, 2022 | ca.finance.yahoo.com

Sports Medicine Market to hit USD 9.5 billion by 2030, says Global Market Insights Inc.

July 4, 2022 | marketwatch.com

Lip Fillers Market SWOT Analysis, Future Growth, Emerging Trends, Latest Innovation, Sales Revenue by Regional Forecast to 2028

July 1, 2022 | marketwatch.com

Hyaluronic Acid Based Dermal Fillers Market Size to reach USD 4884.6 Million [CAGR 7.8%] | Market Rising in United States And Europe

June 4, 2022 | finance.yahoo.com

Insights on the Sodium Hyaluronate-based Products Global Market to 2030 - Featuring Allergan, Cadila Pharmaceuticals and Galderma Among Others

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive ANIK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Anika Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ANIK Company Calendar

Last Earnings: 8/03/2022
Today: 10/07/2022
Next Earnings (Estimated): 11/03/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Surgical & medical instruments
Sub-Industry: Health Care Supplies
Sector: Medical
Current Symbol: NASDAQ:ANIK
CUSIP: 03525510
CIK: 898437
Web: www.anikatherapeutics.com
Phone: (781) 457-9000
Fax: 781-305-9720
Employees: 297
Year Founded: 1992

Price Target and Rating

Average Stock Price Forecast: $41.50
High Stock Price Forecast: $48.00
Low Stock Price Forecast: $35.00
Forecasted Upside/Downside: +68.6%
Consensus Rating: Hold
Rating Score (0-4): 2.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.76)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $4.13 million
Net Margins: -7.26%
Pretax Margin: -9.83%
Return on Equity: -1.96%
Return on Assets: -1.61%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 5.70
Quick Ratio: 4.50

Sales & Book Value

Annual Sales: $147.79 million
Price / Sales: 2.43
Cash Flow: $1.42 per share
Price / Cash Flow: 17.37
Book Value: $19.89 per share
Price / Book: 1.24

Miscellaneous

Outstanding Shares: 14,600,000
Free Float: 14,158,000
Market Cap: $359.45 million
Optionable: Optionable
Beta: 0.89

Social Links

Key Executives

Dr. Cheryl Renee Blanchard Ph.D. (Age 58)
Pres, CEO & Director
Comp: $1.26M

Mr. Michael L. Levitz (Age 48)
Exec. VP, CFO & Treasurer
Comp: $683.14k

Mr. David Colleran (Age 50)
Exec. VP, Gen. Counsel & Corp. Sec.
Comp: $649.06k

Ms. Anne Nunes
VP of Operations

Mr. Mark Namaroff (Age 59)
Exec. Director of Investor Relations & Corp. Communications

Mr. Charles Sherwood III
VP & Corp. Legal Counsel

Mr. James Chase
Sr. VP of International Sales & Marketing

Mr. Bart Bracy
VP of Sales & Marketing of Americas

Mr. Ben Joseph
VP of Commercial & Corp. Devel.

Ms. Lisa Funiciello
VP of HR

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

ANIK Stock - Frequently Asked Questions

Should I buy or sell Anika Therapeutics stock right now?: 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Anika Therapeutics in the last twelve months. There are currently 2 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" ANIK shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ANIK, but not buy additional shares or sell existing shares.
View ANIK analyst ratings or view top-rated stocks.
What is Anika Therapeutics' stock price forecast for 2022?: 2 analysts have issued 1 year target prices for Anika Therapeutics' shares. Their ANIK share price forecasts range from $35.00 to $48.00. On average, they expect the company's stock price to reach $41.50 in the next twelve months. This suggests a possible upside of 68.6% from the stock's current price.
View analysts price targets for ANIK or view top-rated stocks among Wall Street analysts.
How have ANIK shares performed in 2022?: Anika Therapeutics' stock was trading at $35.83 at the beginning of 2022. Since then, ANIK stock has decreased by 31.3% and is now trading at $24.62.
View the best growth stocks for 2022 here.
When is Anika Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, November 3rd 2022.
View our ANIK earnings forecast.
How were Anika Therapeutics' earnings last quarter?: Anika Therapeutics, Inc. (NASDAQ:ANIK) issued its earnings results on Wednesday, August, 3rd. The biotechnology company reported ($0.20) earnings per share for the quarter, beating the consensus estimate of ($0.26) by $0.06. Anika Therapeutics had a negative trailing twelve-month return on equity of 1.96% and a negative net margin of 7.26%. During the same period in the prior year, the company posted $0.09 earnings per share.

What other stocks do shareholders of Anika Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Anika Therapeutics investors own include Alibaba Group (BABA), Broadcom (AVGO), Gilead Sciences (GILD), Micron Technology (MU), Skyworks Solutions (SWKS), Tesla (TSLA), Advanced Micro Devices (AMD), CVS Health (CVS), Enterprise Products Partners (EPD) and Ligand Pharmaceuticals (LGND).
What is Anika Therapeutics' stock symbol?: Anika Therapeutics trades on the NASDAQ under the ticker symbol "ANIK."
How do I buy shares of Anika Therapeutics?: Shares of ANIK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Anika Therapeutics' stock price today?: One share of ANIK stock can currently be purchased for approximately $24.62.
How much money does Anika Therapeutics make?: Anika Therapeutics (NASDAQ:ANIK) has a market capitalization of $359.45 million and generates $147.79 million in revenue each year. The biotechnology company earns $4.13 million in net income (profit) each year or ($0.76) on an earnings per share basis.
How many employees does Anika Therapeutics have?: The company employs 297 workers across the globe.
How can I contact Anika Therapeutics?: Anika Therapeutics' mailing address is 32 WIGGINS AVENUE, BEDFORD MA, 01730. The official website for the company is www.anikatherapeutics.com. The biotechnology company can be reached via phone at (781) 457-9000, via email at investorrelations@anikatherapeutics.com, or via fax at 781-305-9720.

This page (NASDAQ:ANIK) was last updated on 10/7/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Anika Therapeutics - ANIK Stock Forecast, Price & News

Anika Therapeutics MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability